Building Capacity for Injectable Diacetylmorphine and Hydromorphone for the Treatment of Opioid Use Disorder: Identifying Typical Doses

References

• Archambault, L., M. È. Goyer, J. Sabetti, and M. Perreault. 2022. Implementing injectable opioid agonist treatment: A survey of professionals in the field of opioid use disorders. Drugs: Education, Prevention & Policy 30 (4):434–42. doi:10.1080/09687637.2022.2040007.
   Web of Science ®Google Scholar
• Beaumont, S., T. Magel, S. MacDonald, S. Harrison, M. Schechter, and E. Oviedo-Joekes. 2024. Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving Injectable Opioid Agonist Treatment (IOAT). Substance Abuse Treatment, Prevention & Policy 19 (1):1. doi:10.1186/s13011-023-00585-4.
   PubMed Web of Science ®Google Scholar
• British Columbia Centre on Substance Use. 2021. Guidance for Injectable Opioid Agonist Treatment for Opioid Use Disorder. https://www.bccsu.ca/wp-content/uploads/2021/07/BC_iOAT_Guideline.pdf.
   Google Scholar
• Bruneau, J., K. Ahamad, M. È. Goyer, G. Poulin, P. Selby, B. Fischer, T. C. Wild, and E. Wood. 2018. Management of opioid use disorders: A national clinical practice guideline. Canadian Medical Association Journal 190 (9):E247–57. doi:10.1503/cmaj.170958.
   PubMed Web of Science ®Google Scholar
• Canadian Research Initiative in Substance Misuse. 2019. Injectable opioid agonist treatment for opioid use disorder clinical guideline.https://crism.ca/projects/ioat-guideline/.
   Google Scholar
• Canadian Research Initiative in Substance Misuse. 2020. National injectable opioid agonist treatment guideline clinical guideline an operational guidance. https://crism.ca/projects/ioat-guideline.
   Google Scholar
• Chief Public Health Officer Health Professional Forum. 2023. Common definitions on cultural safety. Public Health Agency of Canada. https://www.canada.ca/content/dam/hc-sc/documents/services/publications/health-system-services/chief-public-health-officer-health-professional-forum-common-definitions-cultural-safety/definitions-en2.pdf.
   Google Scholar
• Drewes, A. M., R. D. Jensen, L. M. Nielsen, J. Droney, L. L. Christrup, L. Arendt-Nielsen, J. Riley, and A. Dahan. 2013. Differences between opioids: Pharmacological, experimental, clinical and economical perspectives. British Journal of Clinical Pharmacology 75 (1):60–78. doi:10.1111/J.1365-2125.2012.04317.X.
   PubMed Web of Science ®Google Scholar
• Dunn, K. E., B. Brands, D. C. Marsh, and G. E. Bigelow. 2018. Characterizing the subjective, observer-rated, and physiological effects of hydromorphone relative to heroin in a human laboratory study. Psychopharmacology 235 (4):971–81. doi:10.1007/S00213-017-4814-3.
   PubMed Web of Science ®Google Scholar
• Eap, C. B., T. Buclin, and P. Baumann. 2002. Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clinical Pharmacokinetics 41 (14):1153–93. doi:10.2165/00003088-200241140-00003.
   PubMed Web of Science ®Google Scholar
• Ekman, I., K. Swedberg, C. Taft, A. Lindseth, A. Norberg, E. Brink, J. Carlsson, S. Dahlin-Ivanoff, I.-L. Johansson, K. Kjellgren, et al. 2011. Person-centered care — Ready for prime time. European Journal of Cardiovascular Nursing 10(4):248–51. doi:10.1016/j.ejcnurse.2011.06.008.
   PubMed Web of Science ®Google Scholar
• Faggiano, F., F. Vigna-Taglianti, E. Versino, and P. Lemma. 2003. Methadone maintenance at different dosages for opioid dependence. The Cochrane Database of Systematic Reviews July (3). doi: 10.1002/14651858.CD002208.
   Google Scholar
• Ferri, M., M. Davoli, and C. A. Perucci. 2011. Heroin maintenance for chronic heroin‐dependent individuals. Cochrane Database of Systematic Reviews December (12). doi:10.1002/14651858.CD003410.PUB4.
   Google Scholar
• Jolley, C. J., J. Bell, G. F. Rafferty, J. Moxham, J. Strang, and G. Fischer. 2015. Understanding heroin overdose: A study of the acute respiratory depressant effects of injected pharmaceutical heroin. Public Library of Science One 10 (10):e0140995. doi:10.1371/JOURNAL.PONE.0140995.
   Google Scholar
• Kastelic, A., G. Dubajic, and E. Strbad. 2008. Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with iadequate withdrawal suppression. Addiction (Abingdon, England) 103 (11):1837–46. doi:10.1111/J.1360-0443.2008.02334.X.
   PubMed Web of Science ®Google Scholar
• Kennedy, A. P., K. A. Phillips, D. H. Epstein, D. A. Reamer, J. Schmittner, and K. L. Preston. 2013. A randomized investigation of methadone doses at or over 100 Mg/Day, combined with contingency management. Drug and Alcohol Dependence 130 (1–3):77–84. doi:10.1016/J.DRUGALCDEP.2012.10.025.
   PubMed Web of Science ®Google Scholar
• Marchand, K., S. Beaumont, J. Westfall, S. MacDonald, S. Harrison, D. C. Marsh, M. T. Schechter, and E. Oviedo-Joekes. 2019. Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review. Substance Abuse Treatment, Prevention & Policy 14 (1):1–15. doi:10.1186/S13011-019-0227-0.
   PubMed Web of Science ®Google Scholar
• Marchand, K., J. Foreman, S. MacDonald, S. Harrison, M. T. Schechter, and E. Oviedo-Joekes. 2020. Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment. Substance Abuse Treatment, Prevention & Policy 15 (1):1–9. doi:10.1186/s13011-020-0253-y.
   PubMed Web of Science ®Google Scholar
• Naber, D., and P.D. Christian Haasen. 2006. The German Model Project for Heroin Assisted Treatment of Opioid Dependent Patients - A Multi-Centre, Randomised, Controlled Treatment Study. Germany: Centre for Interdisciplinary Addiction Research of Hamburg University (ZIS). http://www.heroinstudie.de/H-Report_P1_engl.pdf.
   Google Scholar
• Office Fédéral de la Santé Publique. 2004. Manuel Traitement avec prescription d’héroïne: Directives, recommandations, informations. Switzerland. www.admin.ch/bag/sucht/f/index.htm.
   Google Scholar
• Oviedo-Joekes, E., S. Brissette, S. MacDonald, D. Guh, K. Marchand, S. Jutha, S. Harrison, A. Janmohamed, D. Z. Zhang, A. H. Anis, et al. 2017. Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder. Drug and Alcohol Dependence 176(July):55–62. doi:10.1016/j.drugalcdep.2017.02.021.
   PubMedGoogle Scholar
• Oviedo-Joekes, E., S. Brissette, D. C. Marsh, P. Lauzon, D. Guh, A. Anis, and M. T. Schechter. 2009. Diacetylmorphine versus methadone for the treatment of opioid addiction. The New England Journal of Medicine 361 (8):777–86. doi:10.1056/NEJMOA0810635.
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes, E., D. Guh, S. Brissette, K. Marchand, S. MacDonald, K. Lock, S. Harrison, A. Janmohamed, A. H. Anis, M. Krausz, et al. 2016. Hydromorphone compared with diacetylmorphine for long-term opioid dependence. JAMA Psychiatry 73(5):447–55. doi:10.1001/jamapsychiatry.2016.0109.
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes, E., D. C. Marsh, D. Guh, S. Brissette, and M. T. Schechter. 2011. Potency ratio of hydromorphone and diacetylmorphine in substitution treatment for long-term opioid dependency. Journal of Opioid Management 7 (5):371–76. doi:10.5055/jom.2011.0078.
   PubMedGoogle Scholar
• Oviedo-Joekes, E., H. Palis, D. Guh, K. Marchand, S. Brissette, S. Harrison, S. MacDonald, K. Lock, A. H. Anis, D. C. Marsh, et al. 2019. Treatment with injectable hydromorphone: Comparing retention in double blind and open label treatment periods. Journal of Substance Abuse Treatment 101(June):50–54. doi:10.1016/j.jsat.2019.03.012.
   PubMedGoogle Scholar
• Oviedo-Joekes, E., H. Palis, D. Guh, D. C. Marsh, S. MacDonald, S. Harrison, S. Brissette, A. H. Anis, and M. T. Schechter. 2019. Adverse events during treatment induction with injectable diacetylmorphine and hydromorphone for opioid use disorder. Journal of Addiction Medicine 13 (5):354. doi:10.1097/ADM.0000000000000505.
   PubMed Web of Science ®Google Scholar
• Plaza, A., E. Oviedo Joekes, and J. Carles March. 2007. Nursing in an intravenous heroin prescription treatment. Journal of Addictions Nursing 18 (1):13–20. doi:10.1080/10884600601174425.
   Web of Science ®Google Scholar
• Roux, D., and V. Ana. 2017. Despair as a cause of death: More complex than it first appears. American Journal of Public Health 107 (10):1566. doi:10.2105/AJPH.2017.304041.
   PubMed Web of Science ®Google Scholar
• Silverstein, S. M., R. Daniulaityte, S. S. Martins, S. C. Miller, and R. G. Carlson. 2019. ‘Everything is not right anymore’: Buprenorphine experiences in an era of illicit fentanyl. International Journal of Drug Policy 74 (December):76–83. doi:10.1016/j.drugpo.2019.09.003.
   PubMedGoogle Scholar
• Strang, J., T. Groshkova, A. Uchtenhagen, W. Van Den Brink, C. Haasen, M. T. Schechter, N. Lintzeris, J. Bell, A. Pirona, E. Oviedo-Joekes, et al. 2015. Heroin on trial: Systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. The British Journal of Psychiatry 207(1):5–14. doi:10.1192/bjp.bp.114.149195.
   PubMed Web of Science ®Google Scholar
• Tucker, C. M., M. Marsiske, K. G. Rice, J. J. Nielson, and K. Herman. 2011. Patient-centered culturally sensitive health care: Model testing and refinement. Health Psychology: Official Journal of the Division of Health Psychology, American Psychological Association 30 (3):342–50. doi:10.1037/A0022967.
   PubMed Web of Science ®Google Scholar
• van den Brink, W., V. M. Hendriks, P. Blanken, I. A. Huijsman, and J. M. van Ree. 2003. Medical co-prescription of heroin addicts: Two randomized controlled trials. BMJ 327 (7410):310. doi:10.1136/bmj.327.7410.310.
   PubMed Web of Science ®Google Scholar